InvestorsHub Logo
Followers 58
Posts 10018
Boards Moderated 1
Alias Born 09/21/2016

Re: jimmy667 post# 114252

Monday, 08/07/2017 9:27:06 AM

Monday, August 07, 2017 9:27:06 AM

Post# of 457568
Jimmy, agreed...there is a risk of getting off in the weeds w/interpretation but it is low risk to say ...and they know EXACTLY what they are looking for. Yes, of course there is learning still going on but this ain't your father's Oldsmobile any more. Maybe not to late to save FDA which explains their motivation. It's a win-win.

"To our knowledge, this is the first use of this approach in the design of clinical trials for Alzheimer’s disease, Parkinson’s disease and Rett syndrome, and marks a shift towards advancing implementation of precision medicine for these and other neurodegenerative and neurodevelopmental diseases."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News